News
Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback